Research Article
BibTex RIS Cite

Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps

Year 2022, Volume: 7 Issue: 2, 175 - 179, 01.06.2022
https://doi.org/10.26453/otjhs.982252

Abstract

Objective: Coronavirus disease 2019 (COVID-19) is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Type 2 immune response accompanied by type 2 cytokines such as IL-4, IL-5, IL-13, and eosinophilic inflammation, may have a potential protective effect against COVID-19 in chronic rhinosinusitis patients with nasal polyps (CRS + P). In the study, it was aimed to investigation the prevalence and prognosis of COVID-19 in chronic rhinosinusitis patients with nasal polyps (CRS + P).


Materials and Methods: Patients between the ages of 15-65 operated for CRS + P and were compared with the control group in terms of incidence and disease severity.


Results: Covid RT-PCR test was positive in 5.04% of CRS + P patients. This rate was 8.96% in the control group, and the difference between both groups was statistically significant. When the two groups were compared in terms of disease severity, no significant difference was found.


Conclusions: The incidence of COVID-19 was lower in patients with CRS + P. However, further prospective studies are needed to research the relationship between nasal polyp and COVID-19.

References

  • Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. doi:10.4193/Rhin20.600
  • Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. doi:10.1016/j.jaci.2013.02.036
  • Van Bruaene N, Pérez-Novo CA, Basinski TM, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008;121(6):1435-41. doi:10.1016/j.jaci.2008.02.018
  • Wang C, Zhang L. Use of biologics in chronic sinusitis with nasal polyps. Curr Opin Allergy Clin Immunol. 2019;19(4):365-372. doi:10.1097/ACI.0000000000000540
  • Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
  • Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
  • Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. doi:10.1016/j.jaci.2020.04.006
  • Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699-1709. doi:10.1111/all.14289
  • Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741. doi:10.1111/all.14238
  • Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052
  • Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-1448. doi:10.1126/science.abb2762
  • Saheb Sharif-Askari N, Saheb Sharif-Askari F, Alabed M, et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol Ther Methods Clin Dev. 2020;18:1-6. doi:10.1016/j.omtm.2020.05.013
  • Saheb Sharif-Askari F, Saheb Sharif-Askari N, Goel S, et al. Are patients with chronic rhinosinusitis with nasal polyps at a decreased risk of COVID-19 infection? Int Forum Allergy Rhinol. 2020;10(10):1182-1185. doi:10.1002/alr.22672
  • Dembic Z. The cytokines of the immune system: the role of cytokines in disease related to immune response: Academic Press; 2015.
  • Levings MK, Schrader JW. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms. J Immunol. 1999;162(9):5224-9.
  • Velde AA, Huijbens RJ, Heije K, de Vries JE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood. 1990;76(7):1392-7.
  • Li K, Fang Y, Li W, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020;30(8):4407-4416. doi:10.1007/s00330-020-06817-6
  • Wang M, Wang C, Zhang L. Inflammatory endotypes of CRSwNP and responses to COVID-19. Curr Opin Allergy Clin Immunol. 2021;21(1):8-15. doi:10.1097/ACI.0000000000000700
  • Liu S, Zhi Y, Ying S. COVID-19 and asthma: Reflection during the pandemic. Clin Rev Allergy Immunol. 2020;59(1):78-88. doi:10.1007/s12016-020-08797-3
  • Wang C, Lou H, Wang X, et al. Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2015;135(4):922-929.e6. doi:10.1016/j.jaci.2014.10.018
  • Wang M, Bu X, Fang G, et al. Distinct expression of SARS-CoV-2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps. Allergy. 2021;76(3):789-803. doi:10.1111/all.14665
  • Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5

Nazal Polipli Hastalarda COVID-19 İnsidansının ve Prognozunun Değerlendirilmesi

Year 2022, Volume: 7 Issue: 2, 175 - 179, 01.06.2022
https://doi.org/10.26453/otjhs.982252

Abstract

Amaç: Koronavirüs hastalığı 2019 (COVID-19), şiddetli akut solunum sendromu koronavirüs-2'nin (SARS-CoV-2) neden olduğu küresel bir pandemik bulaşıcı hastalıktır. IL-4, IL-5, IL-13 gibi tip 2 sitokinlerin ve eozionifililik enflamasyonun eşlik ettiği tip 2 immün yanıt nazal polipli kronik rinosinüzit (KRS+P) hastalarında COVID-19’a karşı potansiyel koruyucu etkisi olabilir. Bu çalışmada nazal polipli kronik rinosinüzit (KRS+P) hastalarında COVİD-19 sıklığı ve prognozu belirlemek amaçlandı.


Materyal ve Metot: KRS+P nedeniyle ameliyat edilen 15-65 yaş arası hastalar, insidans ve hastalık şiddeti açısından kontrol grubu ile karşılaştırıldı.


Bulgular: KRS+P hastalarının %5,04'ünde Covid RT-PCR testi pozitif çıktı. Kontrol grubunda bu oran %8,96 idi ve her iki grup arasındaki fark istatistiksel olarak anlamlıydı. İki grup hastalık şiddeti açısından karşılaştırıldığında anlamlı bir fark bulunmadı.


Sonuç: KRS+P hastalarında COVID-19 insidansı daha düşüktü. Ancak nazal polip ile COVID-19 arasındaki ilişkiyi araştırmak için daha ileri prospektif çalışmalara ihtiyaç vardır.

References

  • Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464. doi:10.4193/Rhin20.600
  • Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013;131(6):1479-90. doi:10.1016/j.jaci.2013.02.036
  • Van Bruaene N, Pérez-Novo CA, Basinski TM, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008;121(6):1435-41. doi:10.1016/j.jaci.2008.02.018
  • Wang C, Zhang L. Use of biologics in chronic sinusitis with nasal polyps. Curr Opin Allergy Clin Immunol. 2019;19(4):365-372. doi:10.1097/ACI.0000000000000540
  • Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
  • Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
  • Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. doi:10.1016/j.jaci.2020.04.006
  • Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75(7):1699-1709. doi:10.1111/all.14289
  • Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741. doi:10.1111/all.14238
  • Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052
  • Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-1448. doi:10.1126/science.abb2762
  • Saheb Sharif-Askari N, Saheb Sharif-Askari F, Alabed M, et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol Ther Methods Clin Dev. 2020;18:1-6. doi:10.1016/j.omtm.2020.05.013
  • Saheb Sharif-Askari F, Saheb Sharif-Askari N, Goel S, et al. Are patients with chronic rhinosinusitis with nasal polyps at a decreased risk of COVID-19 infection? Int Forum Allergy Rhinol. 2020;10(10):1182-1185. doi:10.1002/alr.22672
  • Dembic Z. The cytokines of the immune system: the role of cytokines in disease related to immune response: Academic Press; 2015.
  • Levings MK, Schrader JW. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms. J Immunol. 1999;162(9):5224-9.
  • Velde AA, Huijbens RJ, Heije K, de Vries JE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood. 1990;76(7):1392-7.
  • Li K, Fang Y, Li W, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020;30(8):4407-4416. doi:10.1007/s00330-020-06817-6
  • Wang M, Wang C, Zhang L. Inflammatory endotypes of CRSwNP and responses to COVID-19. Curr Opin Allergy Clin Immunol. 2021;21(1):8-15. doi:10.1097/ACI.0000000000000700
  • Liu S, Zhi Y, Ying S. COVID-19 and asthma: Reflection during the pandemic. Clin Rev Allergy Immunol. 2020;59(1):78-88. doi:10.1007/s12016-020-08797-3
  • Wang C, Lou H, Wang X, et al. Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2015;135(4):922-929.e6. doi:10.1016/j.jaci.2014.10.018
  • Wang M, Bu X, Fang G, et al. Distinct expression of SARS-CoV-2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps. Allergy. 2021;76(3):789-803. doi:10.1111/all.14665
  • Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481. doi:10.1016/S2213-2600(20)30079-5
There are 22 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Research article
Authors

Necati İlhan 0000-0002-5832-920X

Deniz Demir 0000-0001-7914-2201

Köksal Delibaş 0000-0003-3020-0073

Mehmet Güven 0000-0002-3665-2428

Mahmut Sinan Yılmaz 0000-0002-5323-0059

Ahmet Kara 0000-0003-3600-5957

Publication Date June 1, 2022
Submission Date October 9, 2021
Acceptance Date February 24, 2022
Published in Issue Year 2022 Volume: 7 Issue: 2

Cite

AMA İlhan N, Demir D, Delibaş K, Güven M, Yılmaz MS, Kara A. Evaluation of Incidence and Prognosis of COVID-19 in Patients with Nasal Polyps. OTJHS. June 2022;7(2):175-179. doi:10.26453/otjhs.982252

Creative Commons License

Online Türk Sağlık Bilimleri Dergisi [Online Turkish Journal of Health Sciences (OTJHS)] is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access journal distributed under the terms of the Creative Commons Attribution License (CC BY-NC 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Click here to get help about article submission processes and "Copyright Transfer Form".